Alparis

Alparis is a Swiss biopharmaceutical company dedicated to the development of novel small molecule therapies for rare metabolic and inflammatory disorders. The company's lead candidate, AP-101, is an oral pharmacological chaperone designed to treat Alpha-1 Antitrypsin Deficiency (AATD). By targeting the misfolded Z-variant of the alpha-1 antitrypsin protein, AP-101 aims to restore proper protein folding, thereby reducing toxic liver accumulation and increasing protective levels in the lungs. Alparis was founded by a team of experienced biotechnology executives and is currently advancing its pipeline through early-stage clinical trials. The company's approach leverages deep expertise in protein folding and small molecule drug discovery to address significant unmet medical needs.